Date

4-2024

Project Type

URC Presentation

College or School

PAUL

Class Year

Senior

Major

Finance

Faculty Research Advisor

Steven Irlbeck

Abstract

The impact of the Inflation Reduction Act of 2022 on the financial strategies of pharmaceutical companies is the focus of this study, emphasizing research and development (R&D) and capital expenditures. The act introduces a paradigm shift in U.S. healthcare policy by enabling Medicare to directly negotiate the prices of select drugs. Employing a difference-in-differences analysis framework, this study analyzes data from both treated and control firms from Q1 2020 to Q4 2023 to evaluate the immediate financial responses of pharmaceutical companies to this significant legislative change.

Share

COinS